This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Changing Landscape of Novel Combination Therapies for Patients with Newly Diagnosed, Risk Stratified and Relapsed/Refractory Multiple Myeloma

Changing Landscape of Novel Combination Therapies for Patients with Newly Diagnosed, Risk Stratified and Relapsed/Refractory Multiple Myeloma

Format

Webcast

Time to Complete

1.25 hours

Released

December 20, 2017

Expires

December 20, 2018
Add to Queue


Maximum Credits

1.25 / AMA PRA Category 1 Credit(s)TM
1.25 / CE for Nurses

Accredited Provider

Jointly provided by CancerNet, LLC, and Amedco

Commercial Supporter

Supported by Amgen

Program Description

This webcast is intended to improve care of patients with multiple myeloma (MM) by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of hematologists/oncologists, physician assistants, nurse practitioners, registered nurses, pharmacists and fellows in training involved in the diagnosis and treatment of patients with multiple myeloma.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Identify the shift from palliative 2-drug combinations towards the use of modern, potent, 3- or 4-drug combination regimens in patients with newly diagnosed and smoldering MM
  • Assess the selection and sequencing of 3- or 4-drug combination novel regimens for risk stratified patients with MM
  • Customize the selection, sequencing of drug combination novel therapies for patients with relapsed/refractory MM

Conflict Of Interest Disclosure Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific bestevidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Faculty

Robert Orlowski, MD, PhD
Professor of Medicine
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Orlowski discloses that he is an advisory board member of Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite Pharma, Sanofi-Aventis, Takeda; and received research support from Amgen, BioTheryX, and Spectrum Pharma.

Keith Stewart, MD
Professor of Hematology/Oncology
Polak Professor of Cancer Research
Mayo Clinic in Arizona
Scottsdale, AZ

Dr. Stewart discloses that he is a consultant and an advisor of Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Takeda, Roche, and Seattle Genetics.

Sagar Lonial, MD
Professor and Chair
Hematology & Medical Oncology
Emory University School of Medicine
Atlanta, GA

Dr. Lonial discloses that he is a consultant of Amgen, BMS, Celgene, Janssen, Merck, Novartis, and Takeda.

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE webcast:

Robert Orlowski, MD, discloses that he is an advisory board member of Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite Pharma, Sanofi-Aventis, and Takeda; and received research support from Amgen, BioTheryX, and Spectrum Pharma.

Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.

Credit

1.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and CancerNet, LLC. Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Amedco designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.25

Type

CE for Nurses

Accreditation Statement

Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and CancerNet, LLC.

Designation Statement

This course provides a maximum of 1.25 contact hour.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

The Amedco do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating and receiving CE credit for this webcast. During the period December 20, 2017 through December 20, 2018, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CE information and personal information of CE participants. Third parties receive only aggregated data about CE activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue